SCHEMBL9907708

SCHEMBL9907708

Cc1cc(Cl)ccc1-c1ncc(Cl)c2ccc(C(=O)O)cc12

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.47
KDM5B Q9UGL1 1/20 0.47
HTR5A P47898 3/20 0.46
MRGPRX4 Q96LA9 2/20 0.42
SRD5A2 P31213 2/20 0.42
SRD5A1 P18405 1/20 0.42
PLAU P00749 3/20 0.41
PLG P00747 1/20 0.41
TNKS2 Q9H2K2 1/20 0.40
MAPT P10636 1/20 0.40
MAP2K4 P45985 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TTR P02766 2/20 0.39
GRM2 Q14416 1/20 0.39
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907732 0.88 SRD5A2 (0.49) KDM4CHTR5ASRD5A2SRD5A1PLAU
SCHEMBL9907763 0.88 HTR5A (0.49) KDM4CKDM5BHTR5AMRGPRX4SRD5A2
SCHEMBL9907678 0.88 HTR5A (0.57) HTR5AMRGPRX4PLAUPLGTNKS2
SCHEMBL9907697 0.87 MAP2K4 (0.45) HTR5AMAPTMAP2K4KDM4EALDH1A1
SCHEMBL9907768 0.86 CSNK2A2 (0.52) HTR5APLAUPLGTNKS2CSNK2A2
SCHEMBL9907718 0.85 HTR5A (0.59) KDM4CHTR5AMRGPRX4SRD5A2SRD5A1
SCHEMBL9907682 0.85 HTR5A (0.42) KDM4CKDM5BHTR5APLAUPLG
SCHEMBL9909200 0.84 PLAU (0.51) KDM4CKDM5BHTR5AMRGPRX4SRD5A2
SCHEMBL9907949 0.84 HTR5A (0.67) HTR5A
SCHEMBL9907990 0.84 HTR5A (0.52) HTR5AMRGPRX4SRD5A2SRD5A1PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E KDM4C 1366/4885KDM5B 167/4885HTR5A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.